[1] Salgia R, Singal AG. Hepatocellular carcinoma and other liver lesions. Med Clin North Am, 2014, 98:103-118.
[2] Zhu K, Dai Z, Zhou J. Biomarkers for hepatocellular carcinoma: progression in early diagnosis, prognosis, and personalized therapy. Biomark Res, 2013, 1:10.
[3] Rowell E, Wilson CB. Programming perpetual T helper cell plasticity. Immunity, 2009, 30:7-9.
[4] Guillonneau C, Bezie S, Anegon I. Immunoregulatory properties of the cytokine IL-34. Cell Mol Life Sci, 2017, 74:2569-2586.
[5] Preisser L, Miot C, Le Guillou-Guillemette H, et al. IL-34 and macrophage colony-stimulating factor are overexpressed in hepatitis C virus fibrosis and induce profibrotic macrophages that promote collagen synthesis by hepatic stellate cells. Hepatology, 2014, 60:1879-1890.
[6] Shoji H, Yoshio S, Mano Y, et al. Interleukin-34 as a fibroblast-derived marker of liver fibrosis in patients with non-alcoholic fatty liver disease. Sci Rep, 2016, 6:28814.
[7] Wang Y, Colonna M. Interkeukin-34, a cytokine crucial for the differentiation and maintenance of tissue resident macrophages and Langerhans cells. Eur J Immunol, 2014, 44:1575-1581.
[8] Moon SJ, Hong YS, Ju JH, et al. Increased levels of interleukin 34 in serum and synovial fluid are associated with rheumatoid factor and anticyclic citrullinated peptide antibody titers in patients with rheumatoid arthritis. J Rheumatol, 2013, 40:1842-1849.
[9] Segaliny AI, Mohamadi A, Dizier B, et al. Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment. Int J Cancer, 2015, 137:73-85.
[10] Cheng ST, Tang H, Ren JH, et al. Interleukin-34 inhibits hepatitis B virus replication in vitro and in vivo. PLoS One, 2017, 12:e0179605. |
